Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antitumor Activity
Agonistic antibodies to CD40 and IL-2 induce dendritic and CD8+ cell activity
April 22nd, 2003
The combination of agonistic antibodies to CD40 and IL-2 produced anti-tumor activity by dendritic and CD8+ cells. "In cancer, the coordinate engagement of professional APC and Ag-specific cell-mediated effector cells may be vital for the induction of effective antitumor responses. We speculated that the enhanced differentiation and function of dendritic cells through CD40 engagement combined with IL-2 administration to stimulate T cell expansion would act coordinately to enhance the adaptive immune response against cancer," researchers in the United States report. "In mice bearing orthotopic metastatic renal cell carcinoma, only the combination of...
Source: Cancer Weekly (2003-04-22)
|
